argus

Wockhardt Ltd

NSE: WOCKPHARMAINE049B0102530,949 Cr

Timeline

Time (IST)TypeMEventSrc
07 Jan, 09:04 amPursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - Wockhardt Files Marketing Authorisation Application for WCK 5222 with European Medicines Agency.nse
01 Jan, 05:44 pmPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider, has voluntarily assigned an ESG rating of 73 (Excellent) for the year 2025 as part of its ESG assessment process.nse
31 Dec, 06:22 pmWockhardt Limited has informed the Exchange that SES ESG Research Pvt Ltd, a SEBI registered ESG rating provider, has voluntarily assigned an ESG rating of 67.3 for the Financial Year 2024-25nse
31 Dec, 04:31 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Orderbse
31 Dec, 04:25 pmIn terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( Listing Regulations ), we wish to inform you that the Company is in receipt of the Tax Demand Order dated 26th December, 2025 passed by the Superintendent, Central GST Range-11, Division-III, Ghaziabad for the period FY 2019-20 amounting to Rs. 90,23,518/- (Ninety Lakh Twenty Three Thousand Five Hundred and Ense
31 Dec, 12:34 pmPursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release European Medicines Agency Grants Accelerated Assessment to WCK 5222 ".nse
31 Dec, 12:26 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
16 Dec, 04:42 pmWockhardt Ltd - 532300 - Intimation For Incorporation Of Step-Down Subsidiaries Of The Company.bse
16 Dec, 04:35 pmPursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated three new Wholly Owned Subsidiaries Wockhardt Swiss AG (Switzerland), Wockhardt Suisse USA Holding Corporation (USA) and Wockhardt Suisse USA LLC (USA). Consequent to the incorporation, Wockhardt Swiss AG, Wockhardt Suisse USA Holding Corporationnse
02 Dec, 01:15 pmWockhardt Ltd - 532300 - Reply To Email Related To Volume Movementbse
02 Dec, 11:57 amWockhardt Ltd - 532300 - Clarification sought from Wockhardt Ltdbse
01 Dec, 11:39 amPursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release US FDA Accepts Wockhardt s New Drug Application for Breakthrough Antibiotic Zaynich .nse
01 Dec, 11:38 amWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Nov, 01:09 pmWockhardt Ltd - 532300 - Reply To Your Email Dated 4Th November, 2025 Relating To Volume Movementbse
04 Nov, 11:18 amWockhardt Ltd - 532300 - Clarification sought from Wockhardt Ltdbse
03 Nov, 06:27 pmPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended September 30, 2025, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Comnse
03 Nov, 06:17 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Monitoring Agency Reportbse
03 Nov, 03:35 pmWockhardt Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Submission pursuant to Regulation 30 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 ( Listing Regulations ) - Press Release".nse
03 Nov, 03:31 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
03 Nov, 03:20 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Change in Managementbse
03 Nov, 03:08 pmWockhardt Ltd - 532300 - Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025bse
03 Nov, 02:58 pmWockhardt Limited has informed the Exchange regarding Appointment of Mr. Om Prakash Bhatt as Non- Executive Independent Director of the company w.e.f. November 03, 2025.nse
03 Nov, 02:55 pmWockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
03 Nov, 02:49 pmWockhardt Ltd - 532300 - Board Meeting Outcome for Outcome Of The Board Meetingbse
29 Oct, 10:33 amWockhardt Ltd - 532300 - Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited ('' The Company'').bse
01 Oct, 09:02 amPursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime (WCK 5222) for Treatment of Serious Gram-Negative Infections .nse
01 Oct, 09:00 amWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Sept, 04:16 pmPursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Prestigious Medical and Public Health Journal THE LANCET Regional Health Publishes Pivotal Phase 3 Clinical Study on Miqnaf® (Nafithromycin) A Landmark for India s Antibiotic Innovation .nse
25 Sept, 04:14 pmWockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
12 Sept, 06:16 pmPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider, has voluntarily assigned an ESG rating of 68 (Strong) for the Financial Year 2024-25 as part of its annual ESG assessment process.nse